28263809|t|Supercritical processed starch nanosponge as a carrier for enhancement of dissolution and pharmacological efficacy of fenofibrate
28263809|a|In current study, supercritical processed starch nanosponge (SSNS) used as a carrier for poorly water soluble drug (fenofibrate) to enhance its in-vitro and in-vivo performance. SSNS was prepared by using sol- gel method and effective supercritical drying technique. Fenofibrate was loaded into the SSNS by using solvent immersion method with selected and optimized organic solvent. BET surface area of SSNS was evaluated by nitrogen adsorption/desorption analysis. SSNS and drug loaded SSNS were characterized by DSC, XRPD, FTIR, SEM, Contact angle study and evaluated for in-vitro, in-vivo studies. The results revealed that the formed SSNS material has high surface area (180m2/gm) with pore size (40 nm to 200nm). The DSC and XRPD study revealed the amorphization of drug within a SSNS. SEM study showed the continuous porous structure with differ nanosized pores of SSNS. Contact angle study showed improvement in aqueous wetting property of drug within a SSNS. In-vitro drug release study showed remarkable dissolution enhancement of SSNS formulation as compared to plain drug. In vivo pharmacodynamic study (hyperlipidaemia model) showed SNSS based formulation significantly improved the bioavailability of drug. Thus SSNS carrier system has good potential to be explored as a delivery system for poorly water soluble drugs.
28263809	0	13	Supercritical	T080	C0205556
28263809	24	30	starch	T109,T121,T123	C0038179
28263809	31	41	nanosponge	T122	C0005479
28263809	47	54	carrier	T122	C0013161
28263809	59	70	enhancement	T052	C2349975
28263809	74	85	dissolution	T059	C3830465
28263809	90	105	pharmacological	T169	C0205464
28263809	106	114	efficacy	T080	C0598333
28263809	118	129	fenofibrate	T109,T121	C0033228
28263809	141	146	study	T062	C2603343
28263809	148	161	supercritical	T080	C0205556
28263809	172	178	starch	T109,T121,T123	C0038179
28263809	179	189	nanosponge	T122	C0005479
28263809	191	195	SSNS	T122	C0005479
28263809	207	214	carrier	T122	C0013161
28263809	219	225	poorly	T080	C0205169
28263809	226	231	water	T121,T197	C0043047
28263809	232	239	soluble	T080	C1948047
28263809	240	244	drug	T121	C0013227
28263809	246	257	fenofibrate	T109,T121	C0033228
28263809	262	269	enhance	T052	C2349975
28263809	274	282	in-vitro	T080	C1533691
28263809	287	294	in-vivo	T082	C1515655
28263809	295	306	performance	T052	C1882330
28263809	308	312	SSNS	T122	C0005479
28263809	317	325	prepared	T052	C1521827
28263809	335	350	sol- gel method	T059	C0201683
28263809	355	364	effective	T080	C1704419
28263809	365	395	supercritical drying technique	T059	C3830390
28263809	397	408	Fenofibrate	T109,T121	C0033228
28263809	413	419	loaded	T052	C1708715
28263809	429	433	SSNS	T122	C0005479
28263809	443	467	solvent immersion method	T059	C0201683
28263809	496	511	organic solvent	T109	C0360100
28263809	513	529	BET surface area	T081	C0392762
28263809	533	537	SSNS	T122	C0005479
28263809	542	551	evaluated	T058	C0220825
28263809	555	594	nitrogen adsorption/desorption analysis	T059	C0022885
28263809	596	600	SSNS	T122	C0005479
28263809	605	609	drug	T121	C0013227
28263809	610	616	loaded	T052	C1708715
28263809	617	621	SSNS	T122	C0005479
28263809	627	640	characterized	T052	C1880022
28263809	644	647	DSC	T059	C0006780
28263809	649	653	XRPD	T059,T062	C1135961
28263809	655	659	FTIR	T062	C0206055
28263809	661	664	SEM	T059	C0026020
28263809	666	679	Contact angle	T081	C0392762
28263809	680	685	study	T062	C2603343
28263809	690	699	evaluated	T058	C0220825
28263809	704	712	in-vitro	T080	C1533691
28263809	714	721	in-vivo	T082	C1515655
28263809	735	742	results	T033	C0683954
28263809	768	772	SSNS	T122	C0005479
28263809	773	781	material	T167	C0520510
28263809	786	790	high	T080	C0205250
28263809	791	803	surface area	T081	C0392762
28263809	820	829	pore size	T081	C3829176
28263809	852	855	DSC	T059	C0006780
28263809	860	864	XRPD	T059,T062	C1135961
28263809	865	870	study	T062	C2603343
28263809	884	897	amorphization	T070	C1254365
28263809	901	905	drug	T121	C0013227
28263809	915	919	SSNS	T122	C0005479
28263809	921	924	SEM	T059	C0026020
28263809	925	930	study	T062	C2603343
28263809	942	952	continuous	T078	C0549178
28263809	953	969	porous structure	T082	C0678594
28263809	982	997	nanosized pores	T082	C1881977
28263809	1001	1005	SSNS	T122	C0005479
28263809	1007	1020	Contact angle	T081	C0392762
28263809	1021	1026	study	T062	C2603343
28263809	1034	1045	improvement	T077	C2986411
28263809	1049	1056	aqueous	T080	C0599956
28263809	1057	1073	wetting property	T080	C0162598
28263809	1077	1081	drug	T121	C0013227
28263809	1091	1095	SSNS	T122	C0005479
28263809	1097	1105	In-vitro	T080	C1533691
28263809	1106	1118	drug release	T070	C3850077
28263809	1119	1124	study	T062	C2603343
28263809	1143	1154	dissolution	T059	C3830465
28263809	1155	1166	enhancement	T052	C2349975
28263809	1170	1174	SSNS	T122	C0005479
28263809	1175	1186	formulation	T062	C0524527
28263809	1190	1198	compared	T052	C1707455
28263809	1208	1212	drug	T121	C0013227
28263809	1214	1221	In vivo	T082	C1515655
28263809	1222	1243	pharmacodynamic study	T062	C1709518
28263809	1245	1260	hyperlipidaemia	T047	C0020473
28263809	1261	1266	model	T075	C0026336
28263809	1275	1279	SNSS	T122	C0005479
28263809	1286	1297	formulation	T062	C0524527
28263809	1312	1320	improved	T033	C0184511
28263809	1325	1340	bioavailability	T081	C0005508
28263809	1344	1348	drug	T121	C0013227
28263809	1355	1359	SSNS	T122	C0005479
28263809	1360	1367	carrier	T122	C0013161
28263809	1379	1383	good	T080	C0205170
28263809	1384	1393	potential	T080	C3245505
28263809	1414	1429	delivery system	T074	C0085104
28263809	1434	1440	poorly	T080	C0205169
28263809	1441	1446	water	T121,T197	C0043047
28263809	1447	1454	soluble	T080	C1948047
28263809	1455	1460	drugs	T121	C0013227